Biotech Values

[DewDiligence]

A few observations:

1. SGP has not put anywhere near the same money into its PI program as VRTX has put into 950. This tells me that SGP itself does not view its PI as a top-flight prospect.

2. Until there is evidence to the contrary, IDIX’s NM283 should rank ahead of Roche’s R1626 as the lead candidate in the polymerase space. NM283 is further along in development and it’s a once-daily pill vs BID for R1626.

3. If ribavirin continues to have a place, it will probably have a place in various cocktails, not merely in an all-SGP regimen.

4. The idea that companies like Roche and SGP will attempt to market an all-inclusive cocktail of solely in-house agents is just speculation at this point. I doubt that things will shake out exactly like that.